- Dupilumab is associated with similar clinical benefits for patients with moderate to severe atopic dermatitis in the real world as in clinical trials, according to a retrospective study from Korea.
Why this matters
- Real-world data are needed to confirm results observed in clinical trials.
- At 16 weeks, dupilumab was associated with:
- 77.4% improvement in the Eczema Area and Severity Index (EASI).
- 70.0% improvement by Numerical Rating Scale.
- 60.7% improvement in the Patient-Oriented Eczema Measure.
- 65.0% improvement in the Dermatology Quality of Life Index.
- P<.001 for all.>
- At 16 weeks:
- 92.7% of patients had achieved ≥50% improvement in EASI (EASI 50).
- 63.6% achieved ≥75% improvement in EASI (EASI 75).
- Female sex was associated with good treatment response (EASI 75):
- OR, 5.4 (P=.04).
- Common adverse events included facial erythema (9.9%) and conjunctivitis (5.0%).
- 101 patients with moderate to severe atopic dermatitis were treated with dupilumab for an analysis of effectiveness and safety.
- Funding: None.
- Short study duration.